Previous 10 | Next 10 |
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020 PR Newswire NEWARK, Calif., Nov. 30, 2020 NEWARK, Calif. , Nov. 30, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that th...
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference PR Newswire NEWARK, Calif., Nov. 25, 2020 NEWARK, Calif. , Nov. 25, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that...
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference PR Newswire NEWARK, Calif., Nov. 11, 2020 NEWARK, Calif. , Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that ...
Protagonist (PTGX): Q3 GAAP EPS of -$0.21 beats by $0.40.Revenue of $13.11M (+216.7% Y/Y) beats by $10.96M.Press Release For further details see: Protagonist EPS beats by $0.40, beats on revenue
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update -- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- -- PTG-300 received Europe...
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting PR Newswire NEWARK, Calif., Nov. 4, 2020 NEWARK, Calif. , Nov. 4, 2020 /PRNewswire/ --...
Protagonist Therapeutics to develop oral IL-23 receptor antagonists with Janssen. Aligos Therapeutics initiates ALG-000184 proof-of-concept study. Equillium goes ahead with Phase 3 trial for COVID-19 vaccine. For further details see: Protagonist Janssen Collaboration, An...
Protagonist Therapeutics' (PTGX) two additional oral peptide IL-23 receptor antagonist candidates - PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186) from its collaboration agreement with Johnson & Johnson (JNJ) unit, Janssen Biotech, have been selected for advancement i...
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen PR Newswire NEWARK, Calif., Oct. 29, 2020 NEWARK, Calif. , Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...